Quarter of a century after the case that led to the PBAC's unaccountability loop

In the early years of the program’s modern era, the period following the legislated creation of its current decision-making framework, a small blue pill forced a confrontation that defined and continues to define the limits of industry and patient power and the reach of advisory committee advice. It was most recently seen in the committee's advice on Lilly's much-anticipated diabetes and weight-loss medicine. …